Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL-101 Gene Therapy for ADA-SCID
NCT02999984Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Dec 2016
- Primary completion
- Oct 2018
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of simoladagene autotemcel in severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), sponsored by University of California, Los Angeles. Started Dec 2016; status: completed.
02
Drugs
simoladagene autotemcel
03
Conditions
severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
Beyond the preview
Go deeper on NCT02999984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02999984.